Evaluation of an Advanced, Multimodal Skin Tone Correcting Serum in Participants With Mild-to-Severe Dyschromia and Hyperpigmentation.

BACKGROUND

A new multimodal skin tone correcting serum formulated with b.r.y.t.e.r. (brown, red, and yellow tones with enhanced resurfacing) technology (EV-I) targets brown, red, and yellow dyschromia and acts through 5 pathways of melanin synthesis to reduce pigmentation, resurface and exfoliate skin, and improve overall skin tone.

METHODS

A single-center, open-label, 12-week trial enrolled females with mild-to-severe dyschromia/hyperpigmentation. EV-I was applied twice daily for 12 weeks, with a subset of participants also applying a double-conjugated retinoid/AHA cream (AHARet) nightly. Pigmentation was graded using the Melasma Area and Severity Index (MASI) scale at baseline and at weeks 2, 4, 8, and 12. Skin dullness and texture were assessed using a 6-point grading scale. Erythema and dryness/flaking were assessed using a 4-point grading scale. Participant satisfaction and adverse events (AEs) were collected over 12 weeks.

RESULTS

Sixty-five participants were enrolled (EV-I, n=40; EV-I/AHARet, n=25) with a mean age of 53 years; 78% of participants had Fitzpatrick skin types (FST) I-III, 22% were FST IV-VI. The majority of participants presented with moderate-to-severe dyschromia/hyperpigmentation. Significant percent improvements from baseline were demonstrated based on MASI scores at 12 weeks (EV-I, 42%, EV-I/AHARet, 47% [all, P<.0001]). Significant improvements from baseline were demonstrated in the appearance of skin texture (EV-I, 46%; EV-I/AHARet, 59% [all, P<.0001]) and dullness (EV-I, 47%; EV-I/AHARet, 59% [all, P<.0001]) at 12 weeks. No increases in erythema or dryness/flaking were observed.

CONCLUSIONS

A new multimodal skin tone correcting serum demonstrated significant improvements in MASI scores and in the appearance of skin texture and dullness. Significant improvements were also achieved in participants using both the skin tone correcting serum and double-conjugated retinoid/AHA cream. Participants reported high levels of satisfaction over 12 weeks. &nbsp.